Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04387461 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 13, 2020
Last Update Posted : August 24, 2022
|
Sponsor:
CG Oncology, Inc.
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
CG Oncology, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2023 |
| Estimated Study Completion Date : | June 2023 |